TY  - CHAP
M1  - Book, Section
TI  - Renal Cell Carcinoma
A1  - Walko, Christine M.
A1  - Crona, Daniel J.
A2  - DiPiro, Joseph T.
A2  - Talbert, Robert L.
A2  - Yee, Gary C.
A2  - Matzke, Gary R.
A2  - Wells, Barbara G.
A2  - Posey, L. Michael
Y1  - 2017
N1  - 
T2  - Pharmacotherapy: A Pathophysiologic Approach, 10e
AB  - Content  UpdateJuly  30,  2019Nivolumab  plus  Ipilimumab  for  Advanced  Renal  Cell  Carcinoma:  In  April  2018,  the  FDA  granted  approvals  to  nivolumab  and  ipilimumab  (Opdivo®  and  Yervoy®)  in  combination  for  treatment  of  intermediate-  or  poor-risk,  previously  untreated  advanced  renal  cell  carcinoma.  Nivolumab  is  an  anti-PD-1  antibody,  and  ipilimumab  is  an  anti-CTLA-4  antibody.  In  2015,  nivolumab  was  approved  as  subsequent  therapy  for  patients  with  relapsed  or  metastatic  clear  cell  histology.  The  combination  of  ipilimumab  and  nivolumab  is  a  NCCN  category  1  first-line  therapy  for  patients  with  intermediate-  or  poor-risk  previously  untreated,  relapsed,  or  medically  unresectable  stage  IV  clear  cell  histology  renal  cell  carcinoma.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1164511301
ER  -